Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Exagen (XGN) stocks in Canada

Learn how to easily invest in Exagen stocks.

Exagen Inc
NASDAQ: XGN - USD
$8.58
+ $0.46 ( + 5.67%)
DIAGNOSTICS & RESEARCH

Exagen is a diagnostics & research business based in the US. Exagen stocks (XGN.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $14.35 – a decrease of 10.67% over the previous week. Exagen employs 181 staff and has a trailing 12-month revenue of around $48.3 million.

How to buy shares in Exagen

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – XGN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Exagen stock price (NASDAQ:XGN)

Use our graph to track the performance of XGN stocks over time.

Exagen shares at a glance

Information last updated 2022-01-17.
Latest market close$8.12
52-week range$8.60 - $24.67
50-day moving average $11.02
200-day moving average $13.25
Wall St. target price$24.40
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.56

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Exagen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Exagen price performance over time

Historical closes compared with the close of $8.12 from 2022-01-21

1 week (2022-01-14) -10.67%
1 month (2021-12-23) -26.32%
3 months (2021-10-22) -33.98%
6 months (2021-07-23) -37.59%
1 year (2021-01-22) -49.44%
2 years (2020-01-23) -61.52%
3 years (2019-01-20) N/A
5 years (2017-01-20) N/A

Exagen financials

Revenue TTM $48.3 million
Gross profit TTM $25.4 million
Return on assets TTM -12.38%
Return on equity TTM -34.38%
Profit margin -48.16%
Book value $5.62
Market capitalisation $146.9 million

TTM: trailing 12 months

Exagen share dividends

We're not expecting Exagen to pay a dividend over the next 12 months.

Exagen share price volatility

Over the last 12 months, Exagen's shares have ranged in value from as little as $8.6 up to $24.67. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Exagen's is 0.4996. This would suggest that Exagen's shares are less volatile than average (for this exchange).

Exagen overview

Exagen Inc. develops and commercializes various testing products based on its Cell-Bound Complement Activation Products technology under the AVISE brand in the United States. It enables rheumatologists to enhance care for patients through the diagnosis, prognosis, and monitoring of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company's products also comprise AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of eight autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a ten-biomarker panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with rapid and reliable results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a six-biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine.

Stocks similar to Exagen

Frequently asked questions


Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site